Gene: MAD2L1

4085
HSMAD2|MAD2
mitotic arrest deficient 2 like 1
protein-coding
4q27
Ensembl:ENSG00000164109 MIM:601467 Vega:OTTHUMG00000132967 UniprotKB:Q13257
NC_000004.12
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.660e-1 (AD)  4.650e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RBM110.908
ITFG10.908
ZNF250.903
UCHL50.902
C10orf880.899
XK0.898
HMGCLL10.898
ORC50.895
SYT40.895
KCNIP40.894

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.506
SYDE1-0.498
CCDC102A-0.464
MAGEA12-0.457
RUNX3-0.453
MTRNR2L8-0.452
AJUBA-0.451
C1QTNF1-0.451
EVC2-0.449
CNN2-0.446

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0264861,2,5,6-dibenzanthracene"1,2,5,6-dibenzanthracene results in increased expression of MAD2L1 mRNA"26377693
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Pregnenolone Carbonitrile] results in increased expression of MAD2L1 mRNA"23626729
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of MAD2L1 mRNA"22698814|2890350
C07258116-hydroxycleroda-3,13(14)-dien-15,16-olide"16-hydroxycleroda-3,13(14)-dien-15,16-olide results in decreased expression of MAD2L1 mRNA"21530604
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MAD2L1 mRNA"25510870
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of MAD2L1 mRNA"27291303
C4049102,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in increased expression of MAD2L1 mRNA"20826375
C4049102,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the expression of MAD2L1 mRNA"19414516
C0294972,3-bis(3'-hydroxybenzyl)butyrolactone"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MAD2L1 mRNA"19167446
C0630022,3-dimethoxy-1,4-naphthoquinone"2,3-dimethoxy-1,4-naphthoquinone results in increased expression of MAD2L1 mRNA"19031421
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MAD2L1 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MAD2L1 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MAD2L1 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MAD2L1 mRNA"25510870
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of MAD2L1 mRNA"21346803
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of MAD2L1 mRNA"18648102
C0909424-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Cadmium Chloride promotes the reaction [CDC20 protein binds to CDC27 protein binds to MAD2L1 protein]]20054826
D000082AcetaminophenAcetaminophen results in decreased expression of MAD2L1 mRNA29067470
D016604Aflatoxin B1Aflatoxin B1 affects the expression of MAD2L1 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of MAD2L1 mRNA23630614
D001151ArsenicArsenic affects the methylation of MAD2L1 gene25304211
C006632arsenic trioxidearsenic trioxide results in decreased expression of MAD2L1 mRNA27829220
C015001arsenitearsenite results in decreased expression of MAD2L1 mRNA18929588
D001379AzathioprineAzathioprine results in decreased expression of MAD2L1 mRNA22623647
C547126AZM551248AZM551248 results in increased expression of MAD2L1 mRNA22323515
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased expression of MAD2L1 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MAD2L1 mRNA20064835|2180250
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MAD2L1 mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MAD2L1 mRNA"20382639
D004958EstradiolEstradiol results in increased expression of MAD2L1 mRNA19167446
D004958EstradiolESR1 protein promotes the reaction [Estradiol results in increased expression of MAD2L1 mRNA]25210133
D004958EstradiolEstradiol results in increased expression of MAD2L1 mRNA20826375|2521013
C053541bicalutamidebicalutamide results in decreased expression of MAD2L1 mRNA15638997
C006780bisphenol Abisphenol A affects the expression of MAD2L1 mRNA21786754
C006780bisphenol Abisphenol A results in increased expression of MAD2L1 mRNA29027980
C006780bisphenol Abisphenol A results in decreased expression of MAD2L1 mRNA27979917|2927551
C006780bisphenol Abisphenol A results in decreased expression of MAD2L1 mRNA26063408
C006780bisphenol Abisphenol A results in increased expression of MAD2L1 mRNA20826375
C006780bisphenol Abisphenol A affects the expression of MAD2L1 mRNA21786754
C006780bisphenol A[bisphenol A co-treated with Testosterone] results in decreased expression of MAD2L1 mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of MAD2L1 mRNA25181051|2698221
D002104CadmiumCadmium results in decreased expression of MAD2L1 mRNA21120746
C028031cadmium acetatecadmium acetate results in decreased expression of MAD2L1 mRNA18155341
D019256Cadmium Chloride4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Cadmium Chloride promotes the reaction [CDC20 protein binds to CDC27 protein binds to MAD2L1 protein]]20054826
D019256Cadmium ChlorideCadmium Chloride promotes the reaction [CDC20 protein binds to CDC27 protein binds to MAD2L1 protein]20054826
D019256Cadmium ChlorideCadmium Chloride affects the expression of MAD2L1 mRNA18804290
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of MAD2L1 mRNA17484886
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of MAD2L1 mRNA27339419
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of MAD2L1 mRNA16934159
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of MAD2L1 mRNA28472532
D003300CopperCopper results in increased expression of MAD2L1 mRNA17205981
C464760copper-1,10-phenanthroline"copper-1,10-phenanthroline results in increased expression of MAD2L1 protein"24638265
D019327Copper SulfateCopper Sulfate results in decreased expression of MAD2L1 mRNA19549813
D003375Coumestrol"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MAD2L1 mRNA"19167446
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in increased expression of MAD2L1 mRNA19167446
D003375CoumestrolCoumestrol results in increased expression of MAD2L1 mRNA19167446
D016572CyclosporineCyclosporine results in decreased expression of MAD2L1 mRNA20106945|2163298
D000069439DasatinibDasatinib results in decreased expression of MAD2L1 mRNA20579391
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of MAD2L1 mRNA]27941970
D002945CisplatinCisplatin results in decreased expression of MAD2L1 mRNA27392435
D002945CisplatinCisplatin results in increased phosphorylation of MAD2L1 protein22006019
C000944dicrotophosdicrotophos results in decreased expression of MAD2L1 mRNA28302478
D004041Dietary FatsDietary Fats results in increased expression of MAD2L1 mRNA25016146
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of MAD2L1 mRNA24535843
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of MAD2L1 mRNA17854601
D004052DiethylnitrosamineRB1 protein inhibits the reaction [Diethylnitrosamine results in increased expression of MAD2L1 mRNA]17854601
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of MAD2L1 mRNA16636312
D002117CalcitriolCalcitriol results in decreased expression of MAD2L1 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in decreased expression of MAD2L1 mRNA21592394
C067311docetaxelMAD2L1 protein affects the susceptibility to docetaxel18691855
D004317DoxorubicinDoxorubicin results in decreased expression of MAD2L1 protein15870702
D004317DoxorubicinMAD2L1 protein affects the susceptibility to Doxorubicin16217747
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of MAD2L1 mRNA14976129
C024565ethylene dichlorideethylene dichloride results in decreased expression of MAD2L1 mRNA28189721
C082360fipronilfipronil results in increased expression of MAD2L1 mRNA23962444
D005472FluorouracilFluorouracil affects the expression of MAD2L1 mRNA16557594
D005472FluorouracilFluorouracil results in decreased expression of MAD2L1 mRNA17039268
D005472FluorouracilFluorouracil results in decreased expression of MAD2L1 mRNA19272435
C070081fulvestrant[fulvestrant co-treated with Sirolimus] results in decreased expression of MAD2L1 mRNA19016759
C070081fulvestrantfulvestrant results in decreased expression of MAD2L1 mRNA19016759
C039281furanfuran results in increased expression of MAD2L1 mRNA22079235|2553966
D006046GoldGold results in decreased expression of MAD2L1 mRNA25523186
D006533HeptachlorHeptachlor results in increased expression of MAD2L1 mRNA23153324
D017313FenretinideFenretinide results in increased expression of MAD2L1 mRNA28973697
D006918HydroxyureaHydroxyurea results in decreased expression of MAD2L1 mRNA12929121
D007213IndomethacinIndomethacin results in increased expression of MAD2L1 mRNA28201806
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of MAD2L1 mRNA25613284
C051890irinotecanirinotecan metabolite results in decreased expression of MAD2L1 mRNA15956246
C051890irinotecanirinotecan results in decreased expression of MAD2L1 mRNA15956246
C544151jinfukangjinfukang results in increased expression of MAD2L1 mRNA27392435
C410337K 7174K 7174 results in decreased expression of MAD2L1 mRNA24086573
D008070LipopolysaccharidesLipopolysaccharides affects the expression of MAD2L1 mRNA28070326
D008070LipopolysaccharidesPlant Extracts affects the reaction [Lipopolysaccharides affects the expression of MAD2L1 mRNA]28070326
D008154LucanthoneLucanthone results in decreased expression of MAD2L1 mRNA21148553
D008701MethapyrileneMethapyrilene results in increased expression of MAD2L1 mRNA26558467
C005223methyleugenolmethyleugenol affects the expression of MAD2L1 mRNA26011634
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of MAD2L1 mRNA26011545
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in decreased expression of MAD2L1 mRNA24810058
D009151Mustard GasMustard Gas results in decreased expression of MAD2L1 mRNA25102026
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of MAD2L1 mRNA"15585362
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of MAD2L1 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of MAD2L1 mRNA"25554681
D009532NickelNickel results in increased expression of MAD2L1 mRNA25583101
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of MAD2L1 mRNA25729387
C030110oxaliplatinoxaliplatin results in decreased expression of MAD2L1 mRNA25729387
C011030oxfendazoleoxfendazole results in decreased expression of MAD2L1 mRNA26558467
D010100OxygenOxygen deficiency results in decreased expression of MAD2L1 mRNA26516004
D010126OzoneOzone results in increased expression of MAD2L1 mRNA25658374
D010126OzoneTTPA protein affects the reaction [Ozone results in increased expression of MAD2L1 mRNA]19555225
D017239PaclitaxelMAD2L1 protein affects the susceptibility to Paclitaxel18691855
D017239PaclitaxelPaclitaxel results in decreased expression of MAD2L1 mRNA12929121
D052638Particulate MatterParticulate Matter results in decreased expression of MAD2L1 mRNA28412507
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of MAD2L1 mRNA"25510870
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in decreased expression of MAD2L1 mRNA23948077
D010634Phenobarbital[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of MAD2L1 mRNA24535843
D010634PhenobarbitalNR1I3 protein affects the reaction [Phenobarbital results in increased expression of MAD2L1 mRNA]19482888
D010634PhenobarbitalPhenobarbital affects the expression of MAD2L1 mRNA19136022
D010634PhenobarbitalPhenobarbital results in increased expression of MAD2L1 mRNA19482888|2309116
C006253pirinixic acidpirinixic acid affects the expression of MAD2L1 mRNA19136022
C006253pirinixic acidpirinixic acid results in increased expression of MAD2L1 mRNA17950772|1830175
C006253pirinixic acidPPARA protein promotes the reaction [pirinixic acid results in increased expression of MAD2L1 mRNA]17950772
D010894PiroxicamPiroxicam results in increased expression of MAD2L1 mRNA21858171
D010936Plant ExtractsPlant Extracts affects the reaction [Lipopolysaccharides affects the expression of MAD2L1 mRNA]28070326
D011285Pregnenolone Carbonitrile"[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Pregnenolone Carbonitrile] results in increased expression of MAD2L1 mRNA"23626729
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in increased expression of MAD2L1 mRNA22698814
D011374ProgesteroneProgesterone results in decreased expression of MAD2L1 mRNA16966611
D011398PromethazinePromethazine results in decreased expression of MAD2L1 mRNA26011634
D011398PromethazinePromethazine results in increased expression of MAD2L1 mRNA26558467
C045950propiconazolepropiconazole results in increased expression of MAD2L1 mRNA21278054
C005556propionaldehydepropionaldehyde results in decreased expression of MAD2L1 mRNA26079696
D011441PropylthiouracilPropylthiouracil results in increased expression of MAD2L1 mRNA24780913
D011794QuercetinQuercetin results in decreased expression of MAD2L1 mRNA15309432
C059514resveratrol[Coumestrol co-treated with resveratrol] results in increased expression of MAD2L1 mRNA19167446
C059514resveratrolresveratrol results in decreased expression of MAD2L1 mRNA15767336
C059514resveratrolresveratrol results in increased expression of MAD2L1 mRNA19167446
C059514resveratrolresveratrol results in increased expression of MAD2L1 mRNA16081268
C115461SC 560SC 560 results in decreased expression of MAD2L1 mRNA14633654
C115461SC 560SC 560 results in decreased expression of MAD2L1 protein14633654
D019821SimvastatinSimvastatin results in decreased expression of MAD2L1 mRNA17428261
D020123Sirolimus[fulvestrant co-treated with Sirolimus] results in decreased expression of MAD2L1 mRNA19016759
C009277sodium arsenatesodium arsenate results in decreased expression of MAD2L1 mRNA23922661
C017947sodium arsenitesodium arsenite results in decreased expression of MAD2L1 mRNA12377979
C017947sodium arsenitesodium arsenite results in decreased expression of MAD2L1 mRNA16014739|1799827
C016104sodium bichromatesodium bichromate results in increased expression of MAD2L1 mRNA25993096
D053260SootSoot results in increased expression of MAD2L1 mRNA26551751
C025462sulindac sulfidesulindac sulfide results in decreased expression of MAD2L1 mRNA12734198
C025462sulindac sulfidesulindac sulfide results in decreased expression of MAD2L1 protein12734198
D013739Testosterone[Testosterone co-treated with Calcitriol] results in decreased expression of MAD2L1 mRNA21592394
D013739TestosteroneTestosterone results in decreased expression of MAD2L1 mRNA21592394
D013739Testosterone[bisphenol A co-treated with Testosterone] results in decreased expression of MAD2L1 mRNA26496021
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MAD2L1 mRNA21802500
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MAD2L1 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MAD2L1 protein11479202
D013755Tetradecanoylphorbol AcetateTetradecanoylphorbol Acetate results in increased expression of MAD2L1 mRNA19031421
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of MAD2L1 mRNA25613284
D019284ThapsigarginThapsigargin results in decreased expression of MAD2L1 mRNA22378314
D013853ThioacetamideThioacetamide results in increased expression of MAD2L1 mRNA23411599|2601163
C009495titanium dioxidetitanium dioxide results in increased expression of MAD2L1 mRNA23557971
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of MAD2L1 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of MAD2L1 mRNA25729387
D014212TretinoinTretinoin results in decreased expression of MAD2L1 mRNA21934132
D014241TrichloroethyleneTrichloroethylene results in increased expression of MAD2L1 mRNA25549359
C012589trichostatin Atrichostatin A results in decreased expression of MAD2L1 mRNA23770000
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of MAD2L1 mRNA19042947
C001899triptolidetriptolide results in increased expression of MAD2L1 mRNA23639586
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of MAD2L1 mRNA"26179874
C057693troglitazonetroglitazone results in decreased expression of MAD2L1 mRNA19140230
D014415TunicamycinTunicamycin results in decreased expression of MAD2L1 mRNA22378314
D014640VancomycinVancomycin results in decreased expression of MAD2L1 mRNA18930951
D014747VinblastineMAD2L1 protein affects the susceptibility to Vinblastine16217747
C029297vinylidene chloridevinylidene chloride results in increased expression of MAD2L1 mRNA26682919
C111237vorinostatvorinostat results in increased expression of MAD2L1 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI10200259  10527948  10700282  12006501  15525512  16189514  
16525508  17443180  17443186  18022367  18022368  18318601  
18692475  18794143  18981471  19143472  19273613  19615732  
20133940  20212161  20360068  20951947  21041666  21300909  
21407176  21666598  21772247  21988832  22000412  22340593  
22493223  24581499  25383541  25416956  25422469  25852190  
26258632  26496610  
GO:0042802identical protein binding-IPI16525508  18022367  18318601  21041666  21772247  
GO:0042803protein homodimerization activity-IPI18022367  
GO ID GO Term Qualifier Evidence PubMed
GO:0000070mitotic sister chromatid segregation-IEA-  
GO:0007093mitotic cell cycle checkpoint-IDA8824189  
GO:0007093mitotic cell cycle checkpoint-IGI21274008  
GO:0007094mitotic spindle assembly checkpoint-IEA-  
GO:0031145anaphase-promoting complex-dependent catabolic process-TAS-  
GO:0042177negative regulation of protein catabolic process-IDA11459825  
GO:0043066negative regulation of apoptotic process-IMP20870947  
GO:0045930negative regulation of mitotic cell cycle-IMP21274008  
GO:0051301cell division-IEA-  
GO:0090267positive regulation of mitotic cell cycle spindle assembly checkpoint-IMP20870947  
GO:1904667negative regulation of ubiquitin protein ligase activity-IDA11459825  
GO ID GO Term Qualifier Evidence PubMed
GO:0000776kinetochore-IDA19229290  20133940  
GO:0000776kinetochorecolocalizes_withIDA8824189  17363900  19468067  
GO:0000777condensed chromosome kinetochore-IEA-  
GO:0000922spindle pole-IEA-  
GO:0005634nucleus-IDA18981471  20870947  
GO:0005643nuclear porecolocalizes_withIDA18981471  
GO:0005654nucleoplasm-IDA-  
GO:0005829cytosol-IDA18981471  
GO:0005829cytosol-TAS-  
GO:0048471perinuclear region of cytoplasm-IDA8824189  20870947  
GO:0072686mitotic spindle-IDA20133940  
KEGG ID KEGG Term
hsa04110Cell cycle
hsa04114Oocyte meiosis
hsa04914Progesterone-mediated oocyte maturation
Reactome ID Reactome Term Evidence
R-HSA-141405Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint componentsTAS
R-HSA-141424Amplification of signal from the kinetochoresTAS
R-HSA-141430Inactivation of APC/C via direct inhibition of the APC/C complexTAS
R-HSA-141444Amplification of signal from unattached kinetochores via a MAD2 inhibitory signalTAS
R-HSA-162582Signal TransductionTAS
R-HSA-1640170Cell CycleTAS
R-HSA-174143APC/C-mediated degradation of cell cycle proteinsTAS
R-HSA-174184Cdc20:Phospho-APC/C mediated degradation of Cyclin ATAS
R-HSA-176408Regulation of APC/C activators between G1/S and early anaphaseTAS
R-HSA-176409APC/C:Cdc20 mediated degradation of mitotic proteinsTAS
R-HSA-176814Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteinsTAS
R-HSA-179409APC-Cdc20 mediated degradation of Nek2ATAS
R-HSA-179419APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpointTAS
R-HSA-194315Signaling by Rho GTPasesTAS
R-HSA-195258RHO GTPase EffectorsTAS
R-HSA-2467813Separation of Sister ChromatidsTAS
R-HSA-2500257Resolution of Sister Chromatid CohesionTAS
R-HSA-2555396Mitotic Metaphase and AnaphaseTAS
R-HSA-453276Regulation of mitotic cell cycleTAS
R-HSA-5663220RHO GTPases Activate ForminsTAS
R-HSA-68877Mitotic PrometaphaseTAS
R-HSA-68882Mitotic AnaphaseTAS
R-HSA-68886M PhaseTAS
R-HSA-69278Cell Cycle, MitoticTAS
R-HSA-69618Mitotic Spindle CheckpointTAS
R-HSA-69620Cell Cycle CheckpointsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26183163MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk of colorectal cancer. (2015 Jul 17)Zhong RSci Rep
26439031Identification of potential therapeutic target genes and mechanisms in non-small-cell lung carcinoma in non-smoking women based on bioinformatics analysis. (2015 Sep)Zhou WEur Rev Med Pharmacol Sci